Stockpiling Biologics Under Hatch-Waxman Protection

By Paul Dietze, Whitney Remily, Scott Cunning, C. Kyle Musgrove and Yongjin Zhu ( October 23, 2017, 11:47 AM EDT) -- A recent biosimilars litigation raises issues regarding the scope of the 35 U.S.C. § 271(e)(1) safe harbor provision and whether it protects commercial stockpiling. Amgen Inc. et al. v. Hospira Inc., No. 1:15-cv-839 (D. Del., Sept. 25, 2017). Hospira is seeking approval to market a biosimilar version of Amgen's erythropoeietin ("EPO") anemia treatment. Hospira had manufactured 21 lots of EPO between 2013 and 2015. These lots numbered in the tens of millions of doses. Prior to trial, Hospira filed a motion for summary judgment arguing that its activities were protected by the safe harbor provisions of 35 U.S.C. § 271(e)(1)....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!